康臣药业完成SK-08片剂临床一期试验首批给药

财中社
13 Mar

  3月13日,康臣药业(01681)发布公告,宣布其SK-08片剂的临床一期试验已完成首批受试者的给药。这项试验旨在评估SK-08片剂的安全性、耐受性及药代动力学特征。公告指出,慢性肾病(CKD)是全球公共卫生的重大挑战,患病人数在中国已超过1亿,且发病率持续上升。

  SK-08片剂作为一类创新药,具有全球知识产权,其独特机制为精准靶向可溶性鸟苷酸环化酶(sGC),并在临床前试验中显示出显著的疗效和良好的安全性。

  该公司在公告中强调,SK-08片剂的开发标志着在创新治疗方案方面的一个重要里程碑,未来有望为慢性肾病患者提供新的治疗选择。公司将继续关注肾脏健康,推动早期筛查和预防措施,以应对这一日益严重的健康问题。公告呼吁股东及潜在投资者在买卖公司股份时保持审慎。

(文章来源:财中社)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10